IMU.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:10):

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia...

Stats
Šios dienos apimtis	17.07M
Vidutinė apimtis	15.87M
Rinkos kapitalizacija	578.26M
EPS	$0 ( 2024-03-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.90
ATR14	$0 (0.00%)

Tūris Koreliacija

Ilgas: -0.12 (neutral)

Trumpas: -0.69 (moderate negative)

Signal:(45.931) Neutral

Imugene Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Imugene Ltd Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

Imugene Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$11.78M
Bruto pelnas:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2023
Pajamos:	$11.78M
Bruto pelnas:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2022
Pajamos:	$12.97M
Bruto pelnas:	$10.56M (81.44 %)
EPS:	$-0.00670

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00453

Financial Reports:

No articles found.

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.